Antitumor effect of cordycepin (3′-deoxyadenosine) on mouse melanoma and lung carcinoma cells involves adenosine A3 receptor stimulation

Anticancer Research

Volumn 26, Issue 1 A, 2006, Pages 43-47

  Nakamura, Kazuki ^a   Yoshikawa, Noriko ^a   Yamaguchi, Yu ^a   Kagota, Satomi ^a   Shinozuka, Kazumasa ^a   Kunitomo, Masaru ^a  

^a MUKOGAWA WOMEN'S UNIVERSITY   (Japan)

Author keywords

Adenosine A3 receptor; B16 BL6 mouse melanoma cells; Cordycepin (3 deoxyadenosine); Lewis lung carcinoma cells

Indexed keywords

1,3 DIPROPYLXANTHINE DERIVATIVE; 1,4 DIHYDRO 2 METHYL 6 PHENYL 4 (2 PHENYLETHYNYL) 3,5 PYRIDINEDICARBOXYLIC ACID 5 BENZYL 3 ETHYL ESTER; 2 CHLORO 6 N (3 IODOBENZYL)ADENOSINE 5' N METHYLURONAMIDE; 2 HEXYNYLADENOSINE 5' N ETHYLURONAMIDE; 6 N CYCLOPENTYLADENOSINE; ADENOSINE; ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE A1 RECEPTOR AGONIST; ADENOSINE A1 RECEPTOR ANTAGONIST; ADENOSINE A2A RECEPTOR AGONIST; ADENOSINE A2A RECEPTOR ANTAGONIST; ADENOSINE A2B RECEPTOR; ADENOSINE A2B RECEPTOR AGONIST; ADENOSINE A2B RECEPTOR ANTAGONIST; ADENOSINE A3 RECEPTOR; ADENOSINE A3 RECEPTOR AGONIST; ADENOSINE A3 RECEPTOR ANTAGONIST; ADENOSINE RECEPTOR BLOCKING AGENT; ADENOSINE RECEPTOR STIMULATING AGENT; ALLOXAZINE; CORDYCEPIN; DEOXYADENOSINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG TARGETING; IC 50; LEWIS CARCINOMA; LUNG CARCINOMA; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADENOSINE; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, LEWIS LUNG; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DEOXYADENOSINES; DIHYDROPYRIDINES; DRUG INTERACTIONS; MELANOMA, EXPERIMENTAL; MICE; RECEPTOR, ADENOSINE A3; STIMULATION, CHEMICAL;

EID: 32144458105     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Nakamura K, Konoha K, Yoshikawa N, Yamaguchi Y, Kagota S, Shinozuka K and Kunitomo M: Effect of cordycepin (3′-deoxyadenosine) on hematogenic lung metastatic model mice. In Vivo 19: 137-142, 2005.
2. Yoshikawa N, Nakamura K, Yamaguchi Y, Kagota S, Shinozuka K and Kunitomo M: Antitumour activity of cordycepin in mice. Clin Exp Pharmacol Physiol 31: S51-S53, 2004.
3. Olah ME and Stiles GL: Adenosine receptor subtypes: characterization and therapeutic regulation. Annu Rev Pharmacol Toxicol 55: 581-606, 1995.
4. Klinger M, Freissmuth M and Nanoff C: Adenosine receptors: G protein-mediated signaling and the role of accessory proteins. Cell Signaling 14: 99-108, 2002.
5. 3 adenosine receptor as a new target for cancer therapy and chemoprotection. Exp Cell Res 269: 230-236, 2001.
6. 3 adenosine receptor agonist CF101. Br J Cancer 89: 1552-1558, 2003.
7. 3AR agonist. Anticancer Res 23: 2077-2083, 2003.
8. 3 adenosine receptor. J Cellular Physiol 186: 19-23, 2001.
9. 3 adenosine receptor induce G-CSF production via NF-kappaB activation: a new class of myeloprotective agents. Exp Hematol 30: 1390-1398, 2002.
10. 3 adenosine receptor is highly expressed in tumor versus normal cells: potential target for tumor growth inhibition. Clin Cancer Res 10: 4472-4479, 2004.
11. 3 receptor expressed in Chinese hamster ovary cells to the extracellular signal-regulated kinase 1/2. Mol Pharmacol 6: 1137-1146, 2002.
12. 3 adenosine receptor, enhances the chemotherapeutic effect of 5-fluorouracil in a colon carcinoma murine model. Neoplasia 7: 85-90, 2005.